3.64
0.28 (8.33%)
| Penutupan Terdahulu | 3.36 |
| Buka | 3.40 |
| Jumlah Dagangan | 1,232,627 |
| Purata Dagangan (3B) | 1,030,411 |
| Modal Pasaran | 213,277,440 |
| Harga / Buku (P/B) | 8.44 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2025 - 11 Aug 2025 |
| EPS Cair (TTM) | -3.04 |
| Nisbah Semasa (MRQ) | 1.16 |
| Aliran Tunai Operasi (OCF TTM) | -142.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -102.50 M |
| Pulangan Atas Aset (ROA TTM) | -30.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Omeros Corporation | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.75 |
|
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.40% |
| % Dimiliki oleh Institusi | 47.30% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ingalls & Snyder Llc | 31 Mar 2025 | 3,977,813 |
| Nomura Holdings Inc | 31 Mar 2025 | 679,020 |
| Bank Of Montreal /Can/ | 31 Mar 2025 | 563,095 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 36.00 (D. Boral Capital, 889.01%) | Beli |
| Median | 22.50 (518.13%) | |
| Rendah | 9.00 (HC Wainwright & Co., 147.25%) | Beli |
| Purata | 22.50 (518.13%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 3.44 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 30 Jun 2025 | 36.00 (889.01%) | Beli | 3.00 |
| 13 May 2025 | 36.00 (889.01%) | Beli | 4.43 | |
| HC Wainwright & Co. | 10 Jun 2025 | 9.00 (147.25%) | Beli | 3.88 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 Jun 2025 | Pengumuman | Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA |
| 24 Jun 2025 | Pengumuman | Omeros Announces Webcast Details for Annual Meeting of Shareholders |
| 15 May 2025 | Pengumuman | Omeros Corporation Reports First Quarter 2025 Financial Results |
| 12 May 2025 | Pengumuman | Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026 |
| 12 May 2025 | Pengumuman | Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025 |
| 06 May 2025 | Pengumuman | FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |